David Shavelle, MD
Interventional Cardiology · Long Beach, CANPI 1154315919
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,497 of the $39,418 with a category attached, or 85.0%. 20 manufacturers reported payments, led by Abbott at 57.2% of the total. Reporting peaked in 2024 at $21,514 and has fallen 57.9% since, to $9,058 in 2025.
Across 104 payments — averaging $379.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Edwards Lifesciences$16K
- Boston Scientific$342
- Abiomed$190
- Penumbra, Inc.$166
- Medtronic$100
- plus $452 from 14 others
Across 59 payments — averaging $3964.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$208K
- Abbott$20K
- Accriva Diagnostics Inc.$7K
What the payments were for
- Consulting fees$33,49785%
- Grants$1000%
- Travel & lodging$2,7007%
- Food & beverage$3,1228%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 69 | $22,538 |
| Edwards Lifesciences | 6 | $15,631 |
| Boston Scientific | 6 | $342 |
| Abiomed | 3 | $190 |
| Penumbra, Inc. | 2 | $166 |
| Medtronic | 1 | $100 |
| Angiodynamics, Inc. | 2 | $76 |
| Cardiva Medical, Inc. | 2 | $76 |
| Biotronik Inc. | 1 | $58 |
| Impulse Dynamics (USA) Inc. | 1 | $36 |
| GSK | 1 | $25 |
| AstraZeneca | 1 | $24 |
| Amgen | 1 | $23 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $23 |
| Novartis | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$15,297
- Edwards SAPIEN 3 Transcatheter Heart Valve$8,400
- CardioMEMS HF System$4,027
- Mitra Clip system$545
- MitraClip$286
- Indigo System$150
- GENERAL VASCULAR INTERVENTION$141
- Impella$117
- Micra$100
- GENERAL - STENTS$100
How this compares
$39,418 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $115,589 |
| XareltoRivaroxaban | 29 | $40,530 |
| EntrestoSacubitril/Valsartan | 36 | $33,325 |
| BrilintaTicagrelor | 31 | $28,153 |
| Repatha SureclickEvolocumab | 25 | $14,770 |
| FarxigaDapagliflozin Propanediol | 14 | $12,394 |
| Metoprolol Succinate | 89 | $1,073 |
| Atorvastatin Calcium | 116 | $1,027 |
| Losartan Potassium | 68 | $893 |
| Carvedilol | 64 | $597 |
| Digoxin | 15 | $459 |
| Bumetanide | 14 | $376 |
| Amlodipine Besylate | 42 | $363 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $333 |
| ClopidogrelClopidogrel Bisulfate | 28 | $289 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBrilinta, Farxiga | $24 | $40,54745 claims |
| NovartisEntresto | $21 | $33,32536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Long Beach
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.